NasdaqGS:KRYSBiotechs
Promising Early Data for Inhaled KB707 Could Be a Game Changer for Krystal Biotech (KRYS)
On August 21, 2025, Krystal Biotech announced updated development plans for its investigational immunotherapy KB707, disclosing promising early efficacy and safety data in heavily pre-treated non-small cell lung cancer (NSCLC) patients and prioritizing the inhaled delivery approach.
This update includes evidence of monotherapy activity, durable clinical responses, and ongoing regulatory engagement, highlighting the potential for KB707 to offer new therapeutic options in solid tumor...